Microfluidic cell culture is a promising technology for applications in the drug screening industry. Key benefits include improved biological function, higher-quality cell-based data, reduced reagent consumption, and lower cost. In this work, we demonstrate how a microfluidic cell culture design was adapted to be compatible with the standard 96-well plate format. Key design features include the elimination of tubing and connectors, the ability to maintain long-term continuous perfusion cell culture using a passive gravity-driven pump, and direct analysis on the outlet wells of the microfluidic plate. A single microfluidic culture plate contained eight independent flow units, each with 104 cells at a flow rate of 50 μL/day (6 min residence time). The cytotoxicity of the anticancer drug etoposide was measured on HeLa cells cultured in this format, using a commercial lactate dehydrogenase plate reader assay. The integration of microfluidic cell culture methods with commercial automation capabilities offers an exciting opportunity for improved cell-based screening.